Oxybutynin hydrochloride
Ditropan is a tablet that contains the active substance oxybutynin hydrochloride. The medicine has a relaxing effect on the smooth muscles of the urinary bladder in patients with symptoms of urinary bladder instability.
Ditropan is indicated for the relief of symptoms of urinary bladder instability, with disturbances of urination in patients with a neurogenic bladder - hyperreflexia of the detrusor muscle (symptoms such as urgent urination, incontinence, difficulty urinating).
Ditropan may be used in children aged 5 years or older for the treatment of:
Before starting to use Ditropan, you should discuss it with your doctor or pharmacist.
If any of the above conditions apply to the patient, they should inform their doctor before starting to use the medicine.
Elderly patients (including frail elderly patients)
Elderly patients should exercise caution when using Ditropan, as they may be more sensitive to the side effects of this medicine and have a higher risk of cognitive impairment.
Children and adolescents
Children under 5 years of age
Ditropan is not recommended for use in children under 5 years of age.
Children aged 5 years or older
This medicine should not be given to a child without prior consultation with a doctor. Children may be more sensitive to the side effects of Ditropan.
You should tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
Caution should be exercised when using the following medicines with Ditropan:
Due to the reduced motility of the stomach, Ditropan may affect the absorption of other medicines from the gastrointestinal tract, e.g., it may increase the absorption of digoxin (used to treat arrhythmias) and reduce the absorption of lidocaine (used for local anesthesia), paracetamol (a pain reliever), lithium salts (used to treat bipolar affective disorder), tetracyclines (antibiotics), phenylbutazone (an anti-inflammatory medicine), sulfamethoxazole, cotrimoxazole (antibiotics), and prolonged-release medicines.
Food does not affect the absorption of the medicine from the gastrointestinal tract.
Alcohol may enhance the drowsiness caused by anticholinergic medicines, such as oxybutynin.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, you should consult your doctor before using this medicine.
Pregnancy
Ditropan may be used during pregnancy only if its use is absolutely necessary. This will be decided by your doctor.
Breastfeeding
Small amounts of oxybutynin pass into breast milk. It is not recommended to use Ditropan during breastfeeding.
Ditropan may cause drowsiness and blurred vision. If you experience these symptoms, you should not drive, operate machinery, or perform tasks that may be potentially hazardous.
If your doctor has told you that you have an intolerance to some sugars, you should contact your doctor before taking this medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means that it is considered "sodium-free".
This medicine should always be used as directed by your doctor. If you are unsure, you should consult your doctor.
The tablet can be divided into equal doses.
Dosage
The exact dose will be determined individually by your doctor, although the recommended doses are as follows.
The usual recommended dose is 1 tablet of Ditropan 2 to 3 times a day. The maximum dose should not exceed 4 tablets per day.
The recommended dose is usually half a tablet 2 times a day. The dose can be increased to 1 tablet 2 times a day to achieve an adequate clinical response, provided that the medicine is well tolerated.
Use in children
Children under 5 years of age
Ditropan is not recommended for use in children under 5 years of age.
Children aged 5 years or older
The usual recommended dose is 1 tablet of Ditropan 2 times a day. The dose can then be increased to 1 tablet 2 to 3 times a day.
The maximum dose should not exceed 3 tablets per day.
If you feel that the effect of Ditropan is too strong or too weak, you should consult your doctor.
Method of administration
The tablets are intended for oral use. They have an unpleasant taste and should be swallowed with a glass of water.
Symptoms of overdose:
agitation, agitation, mental disorders, circulatory disorders (flushing, decreased blood pressure, circulatory failure), respiratory failure, and in severe cases, paralysis and coma.
In the case of severe overdose, the patient should be hospitalized and monitored for cardiovascular function.
If you have taken more than the recommended dose of Ditropan, you should immediately consult your doctor or pharmacist.
If you miss a dose of Ditropan, you should take it as soon as possible, unless it is almost time for the next dose. You should not take a double dose to make up for a missed dose. If you are unsure, you should consult your doctor.
If you have any further doubts about the use of this medicine, you should consult your doctor or pharmacist.
Like all medicines, Ditropan can cause side effects, although not everybody gets them.
The following side effects may occur when using Ditropan:
Very common(more than 1 in 10 people):
constipation, nausea, dry mouth, headache, dizziness, drowsiness, blurred vision, dry skin.
Common(less than 1 in 10 people):
diarrhea, vomiting, altered consciousness (disorientation), dry eyes, urinary retention, flushing of the face, rapid or irregular heartbeat.
Uncommon(less than 1 in 100 people):
discomfort in the abdominal cavity, anorexia, decreased appetite, difficulty swallowing.
Frequency not known(cannot be estimated from the available data):
urinary tract infections, gastroesophageal reflux, pseudo-obstruction in patients at high risk (elderly patients or patients with constipation and treated with other medicines that reduce intestinal motility), cognitive impairment, especially in elderly patients, seizures, drowsiness, agitation, anxiety, hallucinations, nightmares, paranoia, symptoms of depression, dependence on oxybutynin (in patients with a history of drug abuse), tachycardia (rapid heart rate), arrhythmias, heat stroke, increased intraocular pressure, narrow-angle glaucoma, pupil dilation, hypersensitivity to light, reduced sweating, allergic reactions, such as: rash, urticaria (local changes in the form of blisters and redness on the skin), angioedema (an allergic reaction characterized by swelling and/or edema, mainly on the face and limbs), hypersensitivity, nosebleeds, muscle disorders (muscle weakness, pain, cramps).
If you experience any side effects, including those not listed in this leaflet, you should inform your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Store in the original packaging. Store at a temperature below 30°C.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Light blue, round, biconvex tablets with the inscription "OXB5" on one side and a dividing line on the other side.
Packaging of 30 tablets in PVC/Aluminum blisters in a cardboard box.
For more detailed information, you should contact the marketing authorization holder or the parallel importer.
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald
Germany
Fidelio Healthcare Limburg GmbH, Mundipharmastrasse 2, 65549 Limburg an der Lahn, Germany
Sanofi Winthrop Industrie, 30-36, Avenue Gustave Eiffel, 37100 Tours, France
Delpharm Dijon, 6, Boulevard de l’Europe, 21800 Quetigny, France
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in France, the country of export:34009 327 307 5 9
327 307-5
Parallel import authorization number:456/16
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.